1 / 16

Redefining Non-small Cell Lung Cancer: The Role of Histology

Redefining Non-small Cell Lung Cancer: The Role of Histology. History of Therapy in Advanced NSCLC: FDA Approval Dates. ECOG 1594: What Did It Teach Us?. Bevacizumab in NSCLC: Key Clinical Outcomes. Grade 3-5 Non-hematologic Toxicity Associated With Bevacizumab. AVAIL Study Design.

rhoslyn-bronwen
Download Presentation

Redefining Non-small Cell Lung Cancer: The Role of Histology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Redefining Non-small Cell Lung Cancer: The Role of Histology

  2. History of Therapy in Advanced NSCLC: FDA Approval Dates

  3. ECOG 1594: What Did It Teach Us?

  4. Bevacizumab in NSCLC: Key Clinical Outcomes

  5. Grade 3-5 Non-hematologic Toxicity Associated With Bevacizumab

  6. AVAIL Study Design

  7. AVAIL: Progression-Free Survival

  8. Study Design: Cisplatin/Pemetrexed vs Cisplatin/Gemcitabine in First-line NSCLC

  9. Cisplatin/Gemcitabine vs Cisplatin/Pemetrexed in Advanced NSCLC

  10. Toxicities Associated With Platinum-Based Combination Chemotherapy in Advanced NSCLC

  11. Phase 3 PointBreak Study Design

  12. PointBreak: Overall Survival From Randomization (Intent-to-Treat)

  13. PointBreak: Prespecified Exploratory Analysis of KM OS from Randomization: Maintenance Group

  14. PointBreak: CTCAEs (Version 3) Possibly Related to Study Drug in Safety Population

More Related